Litcius/Paper detail

An engineered IL-2 partial agonist promotes CD8+ T cell stemness

Fei Mo, Zhiya Yu, Peng Li, Jangsuk Oh, Rosanne Spolski, Liang Zhao, Caleb R. Glassman, Tori N. Yamamoto, Yun Chen, Filip Gołębiowski, Dalton Hermans, Sonia Majri-Morrison, Lora K. Picton, Wei Liao, Min Ren, Xiaoxuan Zhuang, Suman Mitra, Jian-Xin Lin, Luca Gattinoni, Jonathan D. Powell, Nicholas P. Restifo, K. Christopher García, Warren J. Leonard

2021Nature177 citationsDOIOpen Access PDF

Topics & Concepts

Cytotoxic T cellCell biologyT-cell receptorAdoptive cell transferCD8Chimeric antigen receptorCancer researchBiologyStem cellCancer immunotherapyImmunotherapyT cellChemistryImmunologyAntigenImmune systemIn vitroBiochemistryCAR-T cell therapy researchImmune Cell Function and InteractionVirus-based gene therapy research
An engineered IL-2 partial agonist promotes CD8+ T cell stemness | Litcius